Mechanism of action and pure antiandrogenic properties of flutamide

Although treatment of intact adult male rats with the pure antiandrogen flutamide or a luteinizing hormone‐releasing hormone (LHRH) agonist alone leads to partial inhibition of ventral prostate weight, maximal inhibition is achieved by combination of the two drugs. Potentializing effects of the two...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 1993-12, Vol.72 (S12), p.3816-3827
1. Verfasser: Labrie, F.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3827
container_issue S12
container_start_page 3816
container_title Cancer
container_volume 72
creator Labrie, F.
description Although treatment of intact adult male rats with the pure antiandrogen flutamide or a luteinizing hormone‐releasing hormone (LHRH) agonist alone leads to partial inhibition of ventral prostate weight, maximal inhibition is achieved by combination of the two drugs. Potentializing effects of the two compounds were observed even on prostatic ornithine decarboxylase activity. Because LHRH agonists are widely used to achieve medical castration in men treated for prostate cancer, it is of interest to observe that in the dog, known for being the best model for studies of the action of LHRH agonists, flutamide does not interfere with the potent desensitizing action of the LHRH agonist on pituitary LH secretion, thus supporting the combined use of flutamide with an LHRH agonist for maximal androgen blockade without loss of efficiency of the LHRH agonist. Because prostate cancer is known to show a high degree of heterogeneity of its sensitivity to androgens, we analyzed the effect of combined antiandrogen therapy on parameters more sensitive to androgens than ventral prostatic weight itself. In agreement with its pure antiandrogenic characteristics, flutamide alone has no stimulatory effect on the intraprostatic level of mRNA encoding the C1 or C3 component of prostatic binding protein (PBP), whereas cyproterone acetate (CPA), megestrol acetate (MEG), and, especially, medroxyprogesterone acetate (MPA) markedly stimulate PBP‐C1 and PBP‐C3 mRNA levels, an effect reversed by flutamide, thus further supporting the intrinsic androgenic activity of all these steroidal derivatives. Similar androgenic effects of the steroidal derivatives were observed on prostatic ornithine decarboxylase activity. Androgensensitive Shionogi tumor cells were then used to assess the antiandrogenic/androgenic properties of flutamide and the above‐indicated steroidal derivatives. MPA, MEG, CPA as well as spironolactone‐stimulated cell pro‐liferation under both in vivo and in vitro conditions, thus illustrating the intrinsic androgenic activity of all these compounds. Flutamide was inactive by itself and reversed the stimulatory effect of all other compounds, thus indicating its pure antiandrogenic activity. Although castration reduces intraprostatic dihydrotestosterone (DHT) to undetectable levels in the rat and guinea pig, the concentration remains at about 50% of the value found in intact men after castration, thus indicating an important contribution of the adrenals to DHT in the human pros
doi_str_mv 10.1002/1097-0142(19931215)72:12+<3816::AID-CNCR2820721711>3.0.CO;2-3
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76102879</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76102879</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5021-92e1b178e31deb880ced7f9ccc86001e0ad5571650c3b657dfbacf191428a7a33</originalsourceid><addsrcrecordid>eNqNkG9rFDEQh4NY6ln9CMK-EFFkz5nkdpO9ilDWVgvVA1HwjQzZbLZG9s-Z7CL99mZ71wN9Ib7KDPPL8MzD2DnCEgH4K4RCpoAr_hyLQiDH7IXka-QvXwuF-Xp9dvk2LT-Wn7jiIDlKxDdiCctyc8pTcY8tDv_vswUAqDRbia8P2MMQfsRW8kwcs2PFM74q5IKVH6z5rnsXumRoEm1GN_SJ7utkO3kbi9HFxg_Xtncm2fpha_3obJjDTTuNunO1fcSOGt0G-3j_nrAvF-efy_fp1ebdZXl2lZoMOKYFt1ihVFZgbSulwNhaNoUxRuUAaEHXWSYxz8CIKs9k3VTaNFjEU5SWWogT9my3N3L8nGwYqXPB2LbVvR2mQDJH4EoWMfhtFzR-CMHbhrbeddrfEALNkmmWRLMkupNMMtacaJZMFCXTn5JJEFC5IU4zyJM9yFR1tj5s31uN86f7uQ5Gt43XvXHhEBPxXl7kMXa9i_1yrb35f8ZbxH8S_jURvwErCKZ3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76102879</pqid></control><display><type>article</type><title>Mechanism of action and pure antiandrogenic properties of flutamide</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Labrie, F.</creator><creatorcontrib>Labrie, F.</creatorcontrib><description>Although treatment of intact adult male rats with the pure antiandrogen flutamide or a luteinizing hormone‐releasing hormone (LHRH) agonist alone leads to partial inhibition of ventral prostate weight, maximal inhibition is achieved by combination of the two drugs. Potentializing effects of the two compounds were observed even on prostatic ornithine decarboxylase activity. Because LHRH agonists are widely used to achieve medical castration in men treated for prostate cancer, it is of interest to observe that in the dog, known for being the best model for studies of the action of LHRH agonists, flutamide does not interfere with the potent desensitizing action of the LHRH agonist on pituitary LH secretion, thus supporting the combined use of flutamide with an LHRH agonist for maximal androgen blockade without loss of efficiency of the LHRH agonist. Because prostate cancer is known to show a high degree of heterogeneity of its sensitivity to androgens, we analyzed the effect of combined antiandrogen therapy on parameters more sensitive to androgens than ventral prostatic weight itself. In agreement with its pure antiandrogenic characteristics, flutamide alone has no stimulatory effect on the intraprostatic level of mRNA encoding the C1 or C3 component of prostatic binding protein (PBP), whereas cyproterone acetate (CPA), megestrol acetate (MEG), and, especially, medroxyprogesterone acetate (MPA) markedly stimulate PBP‐C1 and PBP‐C3 mRNA levels, an effect reversed by flutamide, thus further supporting the intrinsic androgenic activity of all these steroidal derivatives. Similar androgenic effects of the steroidal derivatives were observed on prostatic ornithine decarboxylase activity. Androgensensitive Shionogi tumor cells were then used to assess the antiandrogenic/androgenic properties of flutamide and the above‐indicated steroidal derivatives. MPA, MEG, CPA as well as spironolactone‐stimulated cell pro‐liferation under both in vivo and in vitro conditions, thus illustrating the intrinsic androgenic activity of all these compounds. Flutamide was inactive by itself and reversed the stimulatory effect of all other compounds, thus indicating its pure antiandrogenic activity. Although castration reduces intraprostatic dihydrotestosterone (DHT) to undetectable levels in the rat and guinea pig, the concentration remains at about 50% of the value found in intact men after castration, thus indicating an important contribution of the adrenals to DHT in the human prostate, a finding that requires the addition of an antiandrogen to block the action of this important amount of DHT remaining after castration.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/1097-0142(19931215)72:12+&lt;3816::AID-CNCR2820721711&gt;3.0.CO;2-3</identifier><identifier>PMID: 8252497</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Androgen Antagonists - pharmacology ; Androgen-Binding Protein - genetics ; Animals ; antiandrogen ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Biological and medical sciences ; Chemotherapy ; cyproterone acetate ; Dihydrotestosterone - analysis ; flutamide ; Flutamide - administration &amp; dosage ; Flutamide - pharmacology ; Gonadotropin-Releasing Hormone - administration &amp; dosage ; Gonadotropin-Releasing Hormone - analogs &amp; derivatives ; Gonadotropin-Releasing Hormone - pharmacology ; Humans ; hydroxy‐flutamide ; Luteinizing Hormone - blood ; Male ; Medical sciences ; medroxyprogesterone acetate ; megestrol acetate ; Orchiectomy ; Ornithine Decarboxylase - metabolism ; Pharmacology. Drug treatments ; Phosphatidylethanolamine Binding Protein ; Prostate - drug effects ; Prostate - enzymology ; Prostatein ; prostatic binding protein ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - pathology ; RNA, Messenger - analysis ; Secretoglobins ; Shionogi ; spironolactones ; Tumor Cells, Cultured - drug effects ; Uteroglobin</subject><ispartof>Cancer, 1993-12, Vol.72 (S12), p.3816-3827</ispartof><rights>Copyright © 1993 American Cancer Society</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c5021-92e1b178e31deb880ced7f9ccc86001e0ad5571650c3b657dfbacf191428a7a33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,777,781,786,787,23911,23912,25121,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3860296$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8252497$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Labrie, F.</creatorcontrib><title>Mechanism of action and pure antiandrogenic properties of flutamide</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Although treatment of intact adult male rats with the pure antiandrogen flutamide or a luteinizing hormone‐releasing hormone (LHRH) agonist alone leads to partial inhibition of ventral prostate weight, maximal inhibition is achieved by combination of the two drugs. Potentializing effects of the two compounds were observed even on prostatic ornithine decarboxylase activity. Because LHRH agonists are widely used to achieve medical castration in men treated for prostate cancer, it is of interest to observe that in the dog, known for being the best model for studies of the action of LHRH agonists, flutamide does not interfere with the potent desensitizing action of the LHRH agonist on pituitary LH secretion, thus supporting the combined use of flutamide with an LHRH agonist for maximal androgen blockade without loss of efficiency of the LHRH agonist. Because prostate cancer is known to show a high degree of heterogeneity of its sensitivity to androgens, we analyzed the effect of combined antiandrogen therapy on parameters more sensitive to androgens than ventral prostatic weight itself. In agreement with its pure antiandrogenic characteristics, flutamide alone has no stimulatory effect on the intraprostatic level of mRNA encoding the C1 or C3 component of prostatic binding protein (PBP), whereas cyproterone acetate (CPA), megestrol acetate (MEG), and, especially, medroxyprogesterone acetate (MPA) markedly stimulate PBP‐C1 and PBP‐C3 mRNA levels, an effect reversed by flutamide, thus further supporting the intrinsic androgenic activity of all these steroidal derivatives. Similar androgenic effects of the steroidal derivatives were observed on prostatic ornithine decarboxylase activity. Androgensensitive Shionogi tumor cells were then used to assess the antiandrogenic/androgenic properties of flutamide and the above‐indicated steroidal derivatives. MPA, MEG, CPA as well as spironolactone‐stimulated cell pro‐liferation under both in vivo and in vitro conditions, thus illustrating the intrinsic androgenic activity of all these compounds. Flutamide was inactive by itself and reversed the stimulatory effect of all other compounds, thus indicating its pure antiandrogenic activity. Although castration reduces intraprostatic dihydrotestosterone (DHT) to undetectable levels in the rat and guinea pig, the concentration remains at about 50% of the value found in intact men after castration, thus indicating an important contribution of the adrenals to DHT in the human prostate, a finding that requires the addition of an antiandrogen to block the action of this important amount of DHT remaining after castration.</description><subject>Androgen Antagonists - pharmacology</subject><subject>Androgen-Binding Protein - genetics</subject><subject>Animals</subject><subject>antiandrogen</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>cyproterone acetate</subject><subject>Dihydrotestosterone - analysis</subject><subject>flutamide</subject><subject>Flutamide - administration &amp; dosage</subject><subject>Flutamide - pharmacology</subject><subject>Gonadotropin-Releasing Hormone - administration &amp; dosage</subject><subject>Gonadotropin-Releasing Hormone - analogs &amp; derivatives</subject><subject>Gonadotropin-Releasing Hormone - pharmacology</subject><subject>Humans</subject><subject>hydroxy‐flutamide</subject><subject>Luteinizing Hormone - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>medroxyprogesterone acetate</subject><subject>megestrol acetate</subject><subject>Orchiectomy</subject><subject>Ornithine Decarboxylase - metabolism</subject><subject>Pharmacology. Drug treatments</subject><subject>Phosphatidylethanolamine Binding Protein</subject><subject>Prostate - drug effects</subject><subject>Prostate - enzymology</subject><subject>Prostatein</subject><subject>prostatic binding protein</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - pathology</subject><subject>RNA, Messenger - analysis</subject><subject>Secretoglobins</subject><subject>Shionogi</subject><subject>spironolactones</subject><subject>Tumor Cells, Cultured - drug effects</subject><subject>Uteroglobin</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkG9rFDEQh4NY6ln9CMK-EFFkz5nkdpO9ilDWVgvVA1HwjQzZbLZG9s-Z7CL99mZ71wN9Ib7KDPPL8MzD2DnCEgH4K4RCpoAr_hyLQiDH7IXka-QvXwuF-Xp9dvk2LT-Wn7jiIDlKxDdiCctyc8pTcY8tDv_vswUAqDRbia8P2MMQfsRW8kwcs2PFM74q5IKVH6z5rnsXumRoEm1GN_SJ7utkO3kbi9HFxg_Xtncm2fpha_3obJjDTTuNunO1fcSOGt0G-3j_nrAvF-efy_fp1ebdZXl2lZoMOKYFt1ihVFZgbSulwNhaNoUxRuUAaEHXWSYxz8CIKs9k3VTaNFjEU5SWWogT9my3N3L8nGwYqXPB2LbVvR2mQDJH4EoWMfhtFzR-CMHbhrbeddrfEALNkmmWRLMkupNMMtacaJZMFCXTn5JJEFC5IU4zyJM9yFR1tj5s31uN86f7uQ5Gt43XvXHhEBPxXl7kMXa9i_1yrb35f8ZbxH8S_jURvwErCKZ3</recordid><startdate>19931215</startdate><enddate>19931215</enddate><creator>Labrie, F.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19931215</creationdate><title>Mechanism of action and pure antiandrogenic properties of flutamide</title><author>Labrie, F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5021-92e1b178e31deb880ced7f9ccc86001e0ad5571650c3b657dfbacf191428a7a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Androgen Antagonists - pharmacology</topic><topic>Androgen-Binding Protein - genetics</topic><topic>Animals</topic><topic>antiandrogen</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>cyproterone acetate</topic><topic>Dihydrotestosterone - analysis</topic><topic>flutamide</topic><topic>Flutamide - administration &amp; dosage</topic><topic>Flutamide - pharmacology</topic><topic>Gonadotropin-Releasing Hormone - administration &amp; dosage</topic><topic>Gonadotropin-Releasing Hormone - analogs &amp; derivatives</topic><topic>Gonadotropin-Releasing Hormone - pharmacology</topic><topic>Humans</topic><topic>hydroxy‐flutamide</topic><topic>Luteinizing Hormone - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>medroxyprogesterone acetate</topic><topic>megestrol acetate</topic><topic>Orchiectomy</topic><topic>Ornithine Decarboxylase - metabolism</topic><topic>Pharmacology. Drug treatments</topic><topic>Phosphatidylethanolamine Binding Protein</topic><topic>Prostate - drug effects</topic><topic>Prostate - enzymology</topic><topic>Prostatein</topic><topic>prostatic binding protein</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - pathology</topic><topic>RNA, Messenger - analysis</topic><topic>Secretoglobins</topic><topic>Shionogi</topic><topic>spironolactones</topic><topic>Tumor Cells, Cultured - drug effects</topic><topic>Uteroglobin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Labrie, F.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Labrie, F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mechanism of action and pure antiandrogenic properties of flutamide</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1993-12-15</date><risdate>1993</risdate><volume>72</volume><issue>S12</issue><spage>3816</spage><epage>3827</epage><pages>3816-3827</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>Although treatment of intact adult male rats with the pure antiandrogen flutamide or a luteinizing hormone‐releasing hormone (LHRH) agonist alone leads to partial inhibition of ventral prostate weight, maximal inhibition is achieved by combination of the two drugs. Potentializing effects of the two compounds were observed even on prostatic ornithine decarboxylase activity. Because LHRH agonists are widely used to achieve medical castration in men treated for prostate cancer, it is of interest to observe that in the dog, known for being the best model for studies of the action of LHRH agonists, flutamide does not interfere with the potent desensitizing action of the LHRH agonist on pituitary LH secretion, thus supporting the combined use of flutamide with an LHRH agonist for maximal androgen blockade without loss of efficiency of the LHRH agonist. Because prostate cancer is known to show a high degree of heterogeneity of its sensitivity to androgens, we analyzed the effect of combined antiandrogen therapy on parameters more sensitive to androgens than ventral prostatic weight itself. In agreement with its pure antiandrogenic characteristics, flutamide alone has no stimulatory effect on the intraprostatic level of mRNA encoding the C1 or C3 component of prostatic binding protein (PBP), whereas cyproterone acetate (CPA), megestrol acetate (MEG), and, especially, medroxyprogesterone acetate (MPA) markedly stimulate PBP‐C1 and PBP‐C3 mRNA levels, an effect reversed by flutamide, thus further supporting the intrinsic androgenic activity of all these steroidal derivatives. Similar androgenic effects of the steroidal derivatives were observed on prostatic ornithine decarboxylase activity. Androgensensitive Shionogi tumor cells were then used to assess the antiandrogenic/androgenic properties of flutamide and the above‐indicated steroidal derivatives. MPA, MEG, CPA as well as spironolactone‐stimulated cell pro‐liferation under both in vivo and in vitro conditions, thus illustrating the intrinsic androgenic activity of all these compounds. Flutamide was inactive by itself and reversed the stimulatory effect of all other compounds, thus indicating its pure antiandrogenic activity. Although castration reduces intraprostatic dihydrotestosterone (DHT) to undetectable levels in the rat and guinea pig, the concentration remains at about 50% of the value found in intact men after castration, thus indicating an important contribution of the adrenals to DHT in the human prostate, a finding that requires the addition of an antiandrogen to block the action of this important amount of DHT remaining after castration.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>8252497</pmid><doi>10.1002/1097-0142(19931215)72:12+&lt;3816::AID-CNCR2820721711&gt;3.0.CO;2-3</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 1993-12, Vol.72 (S12), p.3816-3827
issn 0008-543X
1097-0142
language eng
recordid cdi_proquest_miscellaneous_76102879
source MEDLINE; Alma/SFX Local Collection
subjects Androgen Antagonists - pharmacology
Androgen-Binding Protein - genetics
Animals
antiandrogen
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Biological and medical sciences
Chemotherapy
cyproterone acetate
Dihydrotestosterone - analysis
flutamide
Flutamide - administration & dosage
Flutamide - pharmacology
Gonadotropin-Releasing Hormone - administration & dosage
Gonadotropin-Releasing Hormone - analogs & derivatives
Gonadotropin-Releasing Hormone - pharmacology
Humans
hydroxy‐flutamide
Luteinizing Hormone - blood
Male
Medical sciences
medroxyprogesterone acetate
megestrol acetate
Orchiectomy
Ornithine Decarboxylase - metabolism
Pharmacology. Drug treatments
Phosphatidylethanolamine Binding Protein
Prostate - drug effects
Prostate - enzymology
Prostatein
prostatic binding protein
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - pathology
RNA, Messenger - analysis
Secretoglobins
Shionogi
spironolactones
Tumor Cells, Cultured - drug effects
Uteroglobin
title Mechanism of action and pure antiandrogenic properties of flutamide
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T06%3A47%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mechanism%20of%20action%20and%20pure%20antiandrogenic%20properties%20of%20flutamide&rft.jtitle=Cancer&rft.au=Labrie,%20F.&rft.date=1993-12-15&rft.volume=72&rft.issue=S12&rft.spage=3816&rft.epage=3827&rft.pages=3816-3827&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/1097-0142(19931215)72:12+%3C3816::AID-CNCR2820721711%3E3.0.CO;2-3&rft_dat=%3Cproquest_cross%3E76102879%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76102879&rft_id=info:pmid/8252497&rfr_iscdi=true